Marketer of EpiPenÂ® Auto-Injector, the No. 1 prescribed epinephrine auto-injector, announces additional efforts to increase anaphylaxis awareness, preparedness and access to treatment for those affected by life-threatening allergies
BASKING RIDGE, N.J., April 25, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (Nasdaq: MYL), is celebrating the 25 th anniversary of the U.S. Food and Drug Administration's (FDA) approval of the EpiPen ® (epinephrine) Auto-Injector. This innovative epinephrine auto-injector, the first of its kind, was developed for the emergency treatment of severe allergic reactions (anaphylaxis). Today, with more than 46 million EpiPen Auto-Injectors dispensed, it remains the No. 1 prescribed epinephrine auto-injector. In recognition of this important milestone, Mylan Specialty recently introduced the 25 th anniversary " $0 Co-Pay Offer." As is consistent with Mylan's commitment to providing people access to high quality medicine, this co-pay card is available to both cash-paying and commercially insured patients. Certain restrictions apply. Additional information about the co-pay card is available online at EpiPen.com, and the coupon is available to patients through physicians across the country. The " $0 Co-Pay Offer" is valid for up to three EpiPen 2-Pak ® cartons or EpiPen Jr 2-Pak ® cartons per prescription, as patients may need to access two EpiPen or EpiPen Jr ® (epinephrine) Auto-Injectors in multiple locations. Eligible patients can use the offer with an unlimited number of prescriptions until the coupon offer expires on December 31, 2013. "Mylan has a long-standing dedication to increasing access to epinephrine auto-injectors through innovative access solutions such as the EpiPen4Schools program, and we're pleased to continue that commitment by introducing our $0 Co-Pay Offer," said Heather Bresch, CEO of Mylan. Immediate access to epinephrine, the medication delivered by EpiPen Auto-Injector, is a critical component of an anaphylaxis action plan. Since 2009, EpiPen Auto-Injectors have delivered an injection of epinephrine using built-in needle protection, so people never see or are exposed to the needle before and after use. Those known to be at risk for anaphylaxis should have an action plan that includes avoiding known allergens, recognizing symptoms, having access to two epinephrine auto-injectors at all times and seeking immediate emergency medical care should anaphylaxis occur.